Center for Translational Medicine, the First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
The Key Laboratory for Tumor Precision Medicine of Shaanxi Province, The First Affiliated Hospital, Xi'an Jiaotong University, Xi'an, Shaanxi 710061, China.
Int J Biol Sci. 2022 Jan 1;18(3):1211-1219. doi: 10.7150/ijbs.67529. eCollection 2022.
The replication licensing factors strictly regulate the DNA replication origin licensing process to guarantee the stability of the genome. Numerous experimental studies have recently demonstrated that the replication licensing factors as oncogenes are essential for the occurrence and development of cancers. Drug resistance, being one of the main characteristics of cancer stem cells, can cause a high recurrence rate and a low survival rate in patients with different cancers. However, the function of the replication licensing factors in cancer stemness remains unclear. The following article highlights the most recent research on DNA replication origin licensing factors in cancer and their function in anti-cancer drug resistance. Moreover, this article proposes a new perspective that replication licensing factors as chemotherapy shield affect anti-cancer drug resistance by promoting the stemness of cancer cells.
复制许可因子严格调控 DNA 复制起始许可过程,以确保基因组的稳定性。最近的大量实验研究表明,复制许可因子作为癌基因,对癌症的发生和发展至关重要。耐药性是癌症干细胞的主要特征之一,可导致不同癌症患者的复发率高、生存率低。然而,复制许可因子在癌症干细胞特性中的功能尚不清楚。本文重点介绍了 DNA 复制起始许可因子在癌症中的最新研究及其在抗癌药物耐药性中的作用。此外,本文提出了一个新的观点,即复制许可因子作为化疗屏蔽物,通过促进癌细胞的干性来影响抗癌药物耐药性。